Список литературы

1. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FGFR1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13): 1201 - 1214.

2. Cross N.C., Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008; 119 (4): 199 - 206.

3. Bain B.J. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010; 95 (5): 696 - 698.

4. 1. Klion (http://asheducationbook.hematologylibrary.org/search?author1=Amy+D.+Klion&sortspec=date&submit=Submit)Eosinophilic Myeloproliferative Disorders. ASH Education Book, December 10, 2011 vol. 2011 (no. 1): 257 - 263.

5. Havelange V., Demoulin J-B. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with eosinophilia. Journal of Blood Medicine 2013; 4: 111 - 121.

6. Baccarani M., Cilloni D., Rondoni M., et al. The efficacy of imatinib mesylate in patients with hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92 (9): 1173 - 1179.

7. Gotlib J., Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22 (11): 1999 - 2010.

8. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; Apr; 41 (4): 461 - 476.

9. Chase (http://www.ncbi.nlm.nih.gov/pubmed/?term=Chase%20A%5Bauth%5D) A., Bryant C., Score J., and Cross N.C.P. Ponatinib as a targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; January; 98 (1): 103 - 106.

10. Tefferi A (http://www.ncbi.nlm.nih.gov/pubmed?term=Tefferi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=19472396)., Vardiman J.W (http://www.ncbi.nlm.nih.gov/pubmed?term=Vardiman%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=19472396). Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algoritms. Leukemia 2008; 22: 14 - 22.

11.: 4.

12. Muller A.M., Martens U.M., Hofmann S.C., et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1 - 16.

13. Gotlieb J. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86: 678 - 688.

14. Gleich G.J., Lieferman K.M., Pardanani A., et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002; 359: 1577 - 1578.

15. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis is response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473 - 478.

16. Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391 - 3397.

17. David M., Cross N.C., Burgstaller S., et al. Durable responses to imatinib in patients with PDGFRB fusion-gene positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61 - 64.

18. Немченко И.С., Хорошко Н.Д., Туркина А.Г. с соавт. миелопролиферативное заболевание с гиперэозинофилией: клиническая характеристика и возможности патогенетической терапии. Тер. архив 2005; N 7: с. 90 - 92.

19. Bochner B.S., Gleich G.J. What targeting eosinophils has taught us about their role in disease. J Allergy Clin Immunol 2010; 126: 16 - 25.

20. Klion A.D. How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736 - 3741.

21. Tefferi A., Gotlib J., Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: Point of care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85: 158 - 164.

22. Straumann A. Idiopathic eosinophilic gastrointestinal diseases in adults. Best Practice Res. Clin Gastroenterol 2008; 22: 481 - 496.

23. Sakamoto K., Erdreich-Epstein A., deClerck Y., et al. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992; 14: 348 - 351.

24. Sioka C., Kyritsis A.P. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63: 761 - 767.

25. Jabbour E., Verstovsek S., Giles F., et al. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005; 104: 541 - 546.

26. Хорошко Н.Д., Мокеева Р.А., Туркина А.Г. с соавт. Идиопатический и симптоматический гиперэозинофильные синдромы (сравнительная характеристика на основе 14 наблюдений). Тер. архив. 1997; N 7; с. 26 - 33.

27. Хорошко Н.Д., Мокеева Р.А., Сысоева Е.П. с соавт. Бластный криз в исходе миелопролиферативного варианта идиопатического гиперэозинофильного синдрома. Гематол. и трансфузиол. 2000; т. 45, N 2; с. 37 - 42.

28. Оксфордский центр доказательной медицины. Уровни доказательности (Май 2001). Разработали Боб Филипс К.Б., Дейв Сакетт, Доуг Баденох, Шарон Штраус, Брайен Хайнес, Мартин Давес в ноябре 1998.